Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases

Growth in development, approvals, and revenue of drugs treating rare diseases (orphan drugs) has been increasing over the last four decades, which has drawn substantial attention to these products. Much of this growth has been attributed to the incentives created by the Orphan Drug Act, which includ...

Full description

Saved in:
Bibliographic details
Volume: 34
Main Author: Kerr, Kirk W
Glos, Lukas J
Format: Journal Article
Language: English
Place of publication: New Zealand Springer Nature B.V 01.02.2020
published in: Pharmaceutical medicine Vol. 34; no. 1; pp. 19 - 29
ORCID: 0000-0003-2584-4122
Data of publication: 2020-02-00
ISSN: 1178-2595
1179-1993
EISSN: 1179-1993
Discipline: Pharmacy, Therapeutics, & Pharmacology
Subjects:
Online Access: Fulltext
Database: PubMed
CrossRef
ProQuest Central (Corporate)
Docstoc
Entrepreneurship Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central
Business Premium Collection
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Business Collection
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest One Academic Eastern Edition
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Database information Databases - DBIS